Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO

NCT07152392 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.

NCT NCT07152392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07152392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Lead sponsor
Shanghai Changzheng Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
April 15, 2025
Completion date
April 15, 2035
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid associated ophthalmopathies